Clinical Trial Update: A Study of SHR-2524 Plus Bevacizumab in the First-line Treatment of Advanced Hepatocellular Carcinoma [Phase 1]

View source ↗

Summary

This is a Phase 1 study evaluating SHR-2524 in combination with bevacizumab as first-line therapy for advanced unresectable hepatocellular carcinoma. The trial …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• SHR-2524

Snippet

Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Conditions: Advanced Unresectable Hepatocellular Carcinoma | Phase 1 | Status: NOT_YET_RECRUITING